Gert Zimmer, etc.,al. [preprint]Immunization with a novel RNA replicon vaccine confers long-lasting protection against H5N1 avian influenza virus in 24 bird species. ttps://doi.org/10.1101/2025.01.15.633174
Highly pathogenic avian influenza viruses (HPAIV) of subtype H5N1 (clade 2.3.4.4b) have spread worldwide and caused the death of hundreds of millions of wild birds and domestic poultry. Moreover, spill over of H5N1 HPAIV from infected birds to more than 50 different mammalian species including humans has been recorded. While, licensed vaccines for protection of avian or mammalian species are not yet available, a few candidate vaccines are being trialled. Here, we report on the experimental vaccination of chickens and captive wild birds using a propagation-defective vesicular stomatitis virus (VSV), in which the essential envelope glycoprotein (G) protein gene was replaced by a modified hemagglutinin gene derived from a clade 2.3.4.4b H5N1 isolated in 2022 in the animal park of Bern, Switzerland. VSV?G(H5mb) was produced on helper cells providing the VSV G protein in trans. Specific pathogen-free (SPF) chickens that were immunized twice via the intramuscular route with adjuvant-free VSV?G(H5mb) replicon particles induced high levels of virus-neutralizing serum antibodies and were fully protected against lethal infection by H5N1 HPAIV (clade 2.3.4.4b). Notably, immunized animals did not shed challenge virus from the respiratory or gastrointestinal tract, suggesting that herd immunity can be achieved. The same vaccine was used to immunize a total of 317 captive wild birds at Bern Animal Park and Zoo Basel, representing 24 different species. No vaccine-associated side effects were observed. Birds without previous contact to H5Nx viruses produced high to very high H5-specific neutralizing antibody titers following the second immunization, while birds showing H5-specific antibodies prior to vaccination, already developed high neutralizing antibody titers after a single immunization. One year after vaccination, most animals still showed significant neutralizing antibody titers, indicating that VSV?G(H5mb) is able to induce a long-lasting protective immune response. Our results indicate that VSV?G(H5mb) is an extraordinary safe and highly efficacious vaccine to stop H5N1 replication in various avian species.
See Also:
Latest articles in those days:
- Based on the MaxEnt model the analysis of influencing factors and simulation of potential risk areas of human infection with avian influenza A (H7N9) in China 19 hours ago
- WPRO/WHO: Avian Influenza Weekly Update, 17 January 2025 2 days ago
- Retrospective modelling of the disease and mortality burden of the 1918-1920 influenza pandemic in Zurich, Switzerland 3 days ago
- Avian Influenza incidents and depopulation methods Feb 2022 to June 2024 in U.S. 3 days ago
- [preprint]From Birds to Bovine: A Review and Critical Analysis of the Outbreaks of Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b in the United States 3 days ago
[Go Top] [Close Window]